期刊文献+
共找到1,331篇文章
< 1 2 67 >
每页显示 20 50 100
Overexpression of amplified in breast cancer 1 (AIB1) gene promotes lung adenocarcinoma aggressiveness in vitro and in vivo by upregulating C-X-C motif chemokine receptor 4 被引量:2
1
作者 Liru He Haixia Deng +8 位作者 Shiliang Liu Jiewei Chen Binkui Li Chenyuan Wang Xin Wang Yiguo Jiang Ningfang Ma Mengzhong Liu Dan Xie 《Cancer Communications》 SCIE 2018年第1期572-585,共14页
Background:We previously found that overexpression of the gene known as amplified in breast cancer 1(AIB1)was associated with lymph node metastasis and poor prognosis in patients with lung adenocarcinoma.However,the r... Background:We previously found that overexpression of the gene known as amplified in breast cancer 1(AIB1)was associated with lymph node metastasis and poor prognosis in patients with lung adenocarcinoma.However,the role of AIB1 in that malignancy remains unknown.The present study aimed to investigate the function of AIB1 in the process of lung adenocarcinoma cell metastasis.Methods:A series of in vivo and in vitro assays were performed to elucidate the function of AIB1,while real-time PCR and Western blotting were utilized to identify the potential downstream targets of AIB1 in the process of lung adenocarcinoma metastasis.Rescue experiments and in vitro assays were performed to investigate whether the invasive-ness of AIB1-induced lung adenocarcinoma was mediated by C-X-C motif chemokine receptor 4(CXCR4).Results:The ectopic overexpression of AIB1 in lung adenocarcinoma cells substantially enhanced cell migration and invasive abilities in vitro and tumor metastasis in vivo,whereas the depletion of AIB1 expression substantially inhibited lung adenocarcinoma cell migration and invasion.CXCR4 was identified as a potential downstream target of AIB1 in lung adenocarcinoma.The knockdown of AIB1 greatly reduced CXCR4 gene expression at both the transcription and protein levels,whereas the knockdown of CXCR4 in cells with AIB1 ectopic overexpression diminished AIB1-induced migration and invasion in vitro and tumor metastasis in vivo.Furthermore,we found a significant positive association between the expression of AIB1 and CXCR4 in lung adenocarcinoma patients(183 cases),and the co-overexpression of AIB1 and CXCR4 predicted the poorest prognosis.Conclusions:These findings suggest that AIB1 promotes the aggressiveness of lung adenocarcinoma in vitro and in vivo by upregulating CXCR4 and that it might be usable as a novel prognostic marker and/or therapeutic target for this disease. 展开更多
关键词 Lung adenocarcinoma Amplified in breast cancer 1 C-X-C motif chemokine receptor 4 METASTASIS Prognosis
原文传递
IL-35、Beclin-1在乳腺癌患者外周血中的水平及意义
2
作者 宦宇 黄秋兰 +5 位作者 齐结华 赵斌奇 蔡徐山 吴守乐 张春利 戴清清 《检验医学与临床》 CAS 2024年第12期1683-1686,共4页
目的探讨白细胞介素(IL)-35、自噬相关蛋白Beclin-1在乳腺癌患者外周血中的水平及意义。方法选取2022年5-10月在上海市嘉定区妇幼保健院诊治的原发性乳腺癌女性患者44例(乳腺癌组)、乳腺良性肿瘤女性患者40例(乳腺良性肿瘤组)及体检的... 目的探讨白细胞介素(IL)-35、自噬相关蛋白Beclin-1在乳腺癌患者外周血中的水平及意义。方法选取2022年5-10月在上海市嘉定区妇幼保健院诊治的原发性乳腺癌女性患者44例(乳腺癌组)、乳腺良性肿瘤女性患者40例(乳腺良性肿瘤组)及体检的健康者40例(健康对照组)作为研究对象。采用酶联免疫吸附试验检测并比较各组外周血中IL-35和Beclin-1水平,同时检测乳腺癌患者糖类抗原15-3(CA15-3),比较不同临床病理特征的乳腺癌患者IL-35、Beclin-1、CA15-3水平;分析乳腺癌患者外周血IL-35、Beclin-1、CA15-3水平之间的相关性。结果乳腺癌组和乳腺良性肿瘤组外周血IL-35水平均高于健康对照组(P<0.05),Beclin-1水平均低于健康对照组(P<0.05)。乳腺癌组外周血IL-35水平高于乳腺良性肿瘤组(P<0.05),Beclin-1水平低于乳腺良性肿瘤组(P<0.05)。不同病理分级、淋巴结转移情况的乳腺癌患者外周血IL-35、Beclin-1水平比较,差异均有统计学意义(P<0.05);不同雌激素受体(ER)检测结果的乳腺癌患者外周血IL-35水平比较,差异无统计学意义(P>0.05),而Beclin-1水平比较,差异有统计学意义(P<0.05)。乳腺癌患者外周血IL-35水平与Beclin-1水平呈负相关(r=-0.484,P<0.05);IL-35、Beclin-1水平与CA15-3水平均无相关性(均P>0.05)。结论乳腺癌患者外周血IL-35水平升高、Beclin-1水平降低。不同病理分级、淋巴结转移情况的乳腺癌患者外周血IL-35、Beclin-1水平有明显差异。乳腺癌患者外周血IL-35水平与Beclin-1水平呈负相关,而IL-35、Beclin-1水平与肿瘤标志物CA15-3水平均无关。 展开更多
关键词 白细胞介素-35 BECLIN-1 乳腺癌 糖类抗原15-3 乳腺良性肿瘤
下载PDF
槲皮素通过雌激素受体下调长非编码RNA MALAT-1并发挥抗乳腺癌的作用机制
3
作者 赵梓亦 熊小明 +2 位作者 谢雨鹏 张义文 张翠薇 《中国药理学通报》 CAS CSCD 北大核心 2024年第3期499-505,共7页
目的探索槲皮素抑制乳腺癌细胞恶性生物学行为的分子机制。方法以乳腺癌细胞系MCF-7和MB231作为研究对象,用慢病毒LV-ERα、LV-MALAT-1转染乳腺癌MB231细胞和MCF7细胞,RT-qPCR检测MALAT-1表达,Western blot检测肿瘤细胞中ERα蛋白表达,C... 目的探索槲皮素抑制乳腺癌细胞恶性生物学行为的分子机制。方法以乳腺癌细胞系MCF-7和MB231作为研究对象,用慢病毒LV-ERα、LV-MALAT-1转染乳腺癌MB231细胞和MCF7细胞,RT-qPCR检测MALAT-1表达,Western blot检测肿瘤细胞中ERα蛋白表达,CCK-8细胞实验、平板克隆形成实验检测细胞增殖能力,PI染色法检测细胞周期,通过mRFP-GFP-LC3荧光双标腺病毒转染检测自噬水平,观察槲皮素和雌二醇对乳腺癌细胞增殖能力的影响。结果17β-雌二醇(E2)可以促进乳腺癌细胞MCF-7的增殖,而5μmol·L^(-1)槲皮素可以明显逆转E2对增殖的促进作用(P<0.05)。槲皮素对不表达雌激素受体α(estrogen receptor-α,ERα)的乳腺癌细胞MB231不表现抑制作用;而过表达ERα后,槲皮素则抑制了E2对MB231-ERα的促进作用。同时槲皮素可以抑制E2激活的MALAT-1表达;并且其抑制作用被过表达MALAT-1所逆转,包括细胞增殖,细胞周期进展以及克隆形成能力。结论槲皮素依赖于ERα的表达对乳腺癌的增殖等恶性行为起抑制作用,并且很可能是通过抑制MALAT-1的表达来发挥作用。 展开更多
关键词 乳腺癌 槲皮素 17Β-雌二醇 雌激素受体 MALAT-1 细胞增殖
下载PDF
1STC1在乳腺癌中的作用研究进展
4
作者 戴泽华 侯净 倪青 《河北医药》 CAS 2024年第2期284-288,共5页
乳腺癌是目前全球女性恶性肿瘤发病率最高的一种疾病,是一种高度异质性疾病,可根据其不同分子指标表达分为4种分子亚型,具有不同的组织学、临床行为和预后特征。锡钙素-1(STC1)是一种分泌型糖蛋白激素,目前已被证实可调节钙和磷酸盐的稳... 乳腺癌是目前全球女性恶性肿瘤发病率最高的一种疾病,是一种高度异质性疾病,可根据其不同分子指标表达分为4种分子亚型,具有不同的组织学、临床行为和预后特征。锡钙素-1(STC1)是一种分泌型糖蛋白激素,目前已被证实可调节钙和磷酸盐的稳态,STC1在哺乳动物的各种组织中表达,并参与多种生理和病理生理过程。同时越来越多的证据表明STC1在多种不同类型的肿瘤中起致癌作用。为了进一步理清STC1与乳腺癌之间的关系,通过大量文献阅读及总结,总结分析了STC1与乳腺癌现有的研究数据,探索STC1与乳腺癌发生、发展、治疗预后等一系列的相关证据,并讨论其在乳腺癌各亚型中的潜在作用,为今后的研究找寻方向。 展开更多
关键词 乳腺癌 锡钙素-1 乳腺癌化疗耐药 乳腺癌预后
下载PDF
加味柴胡桂姜汤介导乳腺癌细胞黏附分子PSGL-1改善炎症-黏附-转移作用研究
5
作者 王淼 陈丽华 +3 位作者 李文卉 何美辰 方春平 胡晨霞 《中国药理学通报》 CAS CSCD 北大核心 2024年第4期776-783,共8页
目的研究炎症微环境下黏附分子PSGL-1异常表达对乳腺癌细胞增殖、黏附、侵袭及迁移能力的影响及加味柴胡桂姜汤干预作用机制。方法制备加味柴胡桂姜汤含药血清,选择高转移乳腺癌MDA-MB-231细胞株,筛选药物最佳浓度;运用脂多糖刺激乳腺... 目的研究炎症微环境下黏附分子PSGL-1异常表达对乳腺癌细胞增殖、黏附、侵袭及迁移能力的影响及加味柴胡桂姜汤干预作用机制。方法制备加味柴胡桂姜汤含药血清,选择高转移乳腺癌MDA-MB-231细胞株,筛选药物最佳浓度;运用脂多糖刺激乳腺癌细胞形成炎症微环境模型,将细胞分为空白对照组、LPS模型组、顺铂组、PSGL-1中和抗体组、加味柴胡桂姜汤组、加味柴胡桂姜汤与PSGL-1中和抗体联合组,采用CCK-8法、明胶黏附、Transwell及细胞划痕实验检测细胞增殖、黏附、侵袭和迁移能力;qRT-PCR和Western blot实验检测PSGL-1与其受体及Vimentin等EMT相关基因表达。结果LPS刺激乳腺癌细胞后细胞生物学行为改变,黏附分子及EMT基因表达增加,加味柴胡桂姜汤、PSGL-1中和抗体均能抑制LPS诱导的增强作用,联合组较加味柴胡桂姜汤组抑制作用降低。结论炎症微环境下肿瘤细胞侵袭及迁移能力增强,加味柴胡桂姜汤能够靶向调控PSGL-1抑制乳腺癌细胞侵袭及迁移。 展开更多
关键词 加味柴胡桂姜汤 乳腺癌 PSGL-1 炎症微环境 侵袭 迁移
下载PDF
BMP-6 inhibits microRNA-21 expression in breast cancer through repressing 6EF1 and AP-1 被引量:44
6
作者 Jun Du Shuang Yang Di An Fen Hu Wei Yuan Chunli Zhai Tianhui Zhu 《Cell Research》 SCIE CAS CSCD 2009年第4期487-496,共10页
关键词 骨形态发生蛋白 microRNA 乳腺癌 AP 转录后调控 上皮细胞 非编码RNA 结合位点
下载PDF
YC-1 exerts inhibitory effects on MDA-MB-468 breast cancer cells by targeting EGFR in vitro and in vivo under normoxic condition 被引量:3
7
作者 Ying Cheng Wei Li +3 位作者 Ying Liu Huan-Chen Cheng Jun Ma Lin Qiu 《Chinese Journal of Cancer》 SCIE CAS CSCD 2012年第5期248-256,共9页
3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole(YC-1),the hypoxia-inducible factor-1 alpha(HIF-1α) inhibitor,suppresses tumor proliferation and metastasis by down-regulating HIF-1α expression under hypoxic c... 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole(YC-1),the hypoxia-inducible factor-1 alpha(HIF-1α) inhibitor,suppresses tumor proliferation and metastasis by down-regulating HIF-1α expression under hypoxic conditions.Our previous studies demonstrated that YC-1 inhibited breast cancer cell proliferation under normoxic conditions.In the current study,we investigated the targets of YC-1 and mechanism of its action in MDA-MB-468 breast cancer cells.In the in vitro experiments,we found that YC-1 significantly inhibited MDA-MB-468 cell proliferation in normoxia and hypoxia.Under normoxic conditions,YC-1 induced apoptosis of MDA-MB-468 cells and blocked cell cycle in the G1 phase,and these effects were possibly related to caspase 8,p21,and p27 expression.RT-PCR and Western blotting results showed that YC-1 primarily inhibited HIF-1α at the mRNA and protein levels under hypoxic conditions,but suppressed the expression of epidermal growth factor receptor(EGFR) at the mRNA and protein levels under normoxic conditions.In vivo,YC-1 prolonged survival,increased survival rate,decreased tumor size and metastasis rate,and inhibited tissue EGFR and HIF-1α expression.However,YC-1 exerted no obvious effect on body weight.These results indicate that YC-1 inhibits the proliferation of MDA-MB-468 cells by acting on multiple targets with minimal side effects.Thus,YC-1 is a promising target drug for breast cancer. 展开更多
关键词 缺氧诱导因子-1Α 表皮生长因子受体 乳腺癌细胞 体外实验 体内 WESTERN印迹 HIF-1 细胞增殖
下载PDF
Effects of Notch-1 Down-regulation on Malignant Behaviors of Breast Cancer Stem Cells 被引量:8
8
作者 彭功玲 田野 +6 位作者 逯翀 郭辉 赵向旺 郭雅文 王龙强 杜秋丽 刘春萍 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2014年第2期195-200,共6页
This study examined the effect of Notch-1 signaling on malignant behaviors of breast cancer cells by regulating breast cancer stem cells (BCSCs). BCSCs were enriched by using serum-free me- dium and knocked out of N... This study examined the effect of Notch-1 signaling on malignant behaviors of breast cancer cells by regulating breast cancer stem cells (BCSCs). BCSCs were enriched by using serum-free me- dium and knocked out of Notch-1 by using a lentiviral vector. Real-time polymerase chain reaction (RT-PCR) and Western blotting were used to detect the Notch-1 expression levels in breast cancer cell lines and BCSCs, and fl0w cytometry to detect the proportion of BCSCs in BCSC spheres. The BCSC self-renewal, migration, invasion, and tumorigenicity were examined by the tumor microsphere-forming assay and transwell assay and after xenotransplantation. The results showed that the Notch-1 silencing reduced the number of BCSC spheres, the proportion of BCSCs, and the number of cells penetrating through the transwell membrane. It also decreased the size of tumors that were implanted in the nude mice. These results suggest that Notch-1 signaling is intimately linked to the behaviors of BCSCs. Blocking Notch-1 signaling can inhibit the malignant behaviors of BCSCs, which may provide a prom- ising therapeutical approach for breast cancer. 展开更多
关键词 NOTCH-1 breast cancer cancer stem cells tumor metastasis TUMORIGENESIS
下载PDF
乳腺癌中BACH 1、HO-1的表达及丹皮酚的调控研究
9
作者 杨芳芳 李睿慧 王建杰 《黑龙江医药科学》 2024年第1期10-12,共3页
目的:探讨乳腺癌(breast cancer,BC)患者癌组织中转录因子BTB-CNC同源体1(BTB and CNC homology,BACH 1)、血红素环氧化酶1(hemoxygenas-1,HO-1)的表达及与乳腺癌临床特征的相关性,进一步研究丹皮酚(paeonol,Pae)对BACH 1、HO-1的表达... 目的:探讨乳腺癌(breast cancer,BC)患者癌组织中转录因子BTB-CNC同源体1(BTB and CNC homology,BACH 1)、血红素环氧化酶1(hemoxygenas-1,HO-1)的表达及与乳腺癌临床特征的相关性,进一步研究丹皮酚(paeonol,Pae)对BACH 1、HO-1的表达调控。方法:免疫组织化学方法检测乳腺癌组织与癌旁组织中BACH 1、HO-1分子的表达,分析BACH 1、HO-1表达与患者临床病理因素之间的关系;体外培养人MDA-MB-468乳腺癌细胞,给予丹皮酚处理48 h,通过CCK-8、Transwell检测细胞的增殖、迁移,Western blot检测BACH 1、HO-1的表达。结果:与非癌组织相比,BACH 1在乳腺癌组织中低表达,与TNM分级显著相关(P<0.05)。HO-1高表达与肿瘤分级显著相关(P<0.05)。CCK-8、Transwell结果显示丹皮酚抑制细胞增殖并减少肿瘤细胞迁移。Western blot结果显示丹皮酚60 mg/L使BACH 1表达上调,HO-1表达下降。结论:BACH 1、HO-1参与乳腺癌发病过程,可作为乳腺癌的预后参考标志物。丹皮酚可抑制乳腺癌细胞增殖迁移,可能与调控BACH 1、HO-1的表达有关。 展开更多
关键词 乳腺癌 BACH 1 HO-1 丹皮酚
下载PDF
Prognostic significance of MDR-1 P-glycoprotein expression in breast cancer 被引量:2
10
作者 Huilin Zhang Wandong Zhang Fengshan Li 《Journal of Nanjing Medical University》 2008年第3期148-152,共5页
Objective: To investigate the expression of MDR-1 P-glycoprotein(MDR-1 Pgp) in breast cancer and analyze its correlation to the biological behavior and prognosis of the disease. Methods:The expression of MDR-1 Pgp... Objective: To investigate the expression of MDR-1 P-glycoprotein(MDR-1 Pgp) in breast cancer and analyze its correlation to the biological behavior and prognosis of the disease. Methods:The expression of MDR-1 Pgp was examined in 75 cases of breast cancer patients by using three different monoclonal antibodies(JSB1, C219 and C494) with S-P immunohistochemisty. These patients were followed up for 5 years, and the correlation between MDR-1 Pgp expression, survival rate and lymph metastasis was analyzed. Results: Positive detection of MDR-1 Pgp by JSB1, C219 and C494 in 75 cases of breast cancer was 86.7%, 48% and 85.3%, respectively. MDR-1 Pgp expression was not related to ages of patients (P 〉 0.05). JSBl-detected expression of MDR-1 Pgp was related to lymph node metastasis(P〈 0.05); while C219 and C494 were not(P 〉 0.05). The patients with MDR-1 Pgp expression positively detected by either two of the three antibodies, had five-year survival rate that was significantly higher than those positively detected by all the three antibodies(P 〈 0.05). Conclusion:Three antibodies should be used simultaneously to detect MDR-1 Pgp expression in breast cancer. Positive MDR-1 Pgp expression in breast cancer detected by all the three antibodies may represent a poor prognosis; while positive MDR-1 Pgp detection by JSB1 and C494 is associated with lymph metastasis. 展开更多
关键词 breast cancer MDR-1 P-glycoprotein IMMUNOHISTOCHEMISTRY PROGNOSIS METASTASIS
下载PDF
Effects of 5-Aza-CdR on the Proliferation of Human Breast Cancer Cell Line MCF-7 and on the Expression of Apaf-1 Gene 被引量:5
11
作者 熊慧华 邱红 +3 位作者 庄亮 熊华 姜蕊 陈元 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2009年第4期498-502,共5页
Hypermethylation in the promoter region of tumor suppressor genes is a common mechanism of gene silencing, which tends to occur in cancer. The effects of 5-Aza-2'-deoxycytidine (5-Aza-CdR), a specific DNA methyltra... Hypermethylation in the promoter region of tumor suppressor genes is a common mechanism of gene silencing, which tends to occur in cancer. The effects of 5-Aza-2'-deoxycytidine (5-Aza-CdR), a specific DNA methyltransferase inhibitor, on the cell proliferation of human breast cancer cell line MCF-7 and on the expression of Apaf-1 gene were investigated. Human MCF-7 cells were incubated with increasing concentrations of 5-Aza-CdR for 12 to 120 h. The growth inhibition rates of MCF-7 cells were detected by MTT assay. Changes of cell cycle distribution and apoptotic rates of MCF-7 cells were determined by flow cytometry. The expressions of DNA methyltransferase 3b mRNA and Apaf-1 mRNA were measured by reverse transcription polymerase chain reaction (RT-PCR). Meanwhile, the expression of Apaf-1 protein was detected by Western blotting. The results showed that 5-Aza-CdR significantly inhibited the growth of MCF-7 cells and the growth inhibition rate of MCF-7 cells was significantly enhanced with the concentration of 5-Aza-CdR and the action time. Flow cytometry indicated that 5-Aza-CdR could significantly induce G1/S cell cycle arrest and increase the apoptosis rate of MCF-7 cells. The mRNA and protein expressions of Apaf-1 were up-regulated in MCF-7 cells treated with 5-Aza-CdR, which was accompanied by down-regulation of DNA methyltransferase 3b mRNA. It is concluded that 5-Aza-CdR might retard the growth of tumor ceils and promote the apoptosis of MCF-7 breast cancer cells by inhibiting the expression of DNA methyltransferase 3b and re-activating the Apaf-1 gene expression. 展开更多
关键词 Apaf-1 gene breast cancer DNA methyltransferase
下载PDF
MicroRNA-26b下调MALAT-1抑制乳腺癌MCF-7细胞恶性生物学行为的机制研究
12
作者 阮思蓓 熊小明 +2 位作者 赵梓亦 杨青坤 张翠薇 《中国现代医学杂志》 CAS 2024年第12期17-23,共7页
目的 探索microRNA-26b(miR-26b)通过MALAT-1抑制乳腺癌MCF-7细胞恶性生物学行为的分子机制。方法 以乳腺癌细胞系MCF-7作为研究对象,采用慢病毒LV-miR-26b-ctrl和LV-miR-26b转染肿瘤细胞,逆转录聚合酶链反应检测MALAT-1、miR-26a和miR-... 目的 探索microRNA-26b(miR-26b)通过MALAT-1抑制乳腺癌MCF-7细胞恶性生物学行为的分子机制。方法 以乳腺癌细胞系MCF-7作为研究对象,采用慢病毒LV-miR-26b-ctrl和LV-miR-26b转染肿瘤细胞,逆转录聚合酶链反应检测MALAT-1、miR-26a和miR-26b的mRNA表达,平板克隆形成实验、CCK-8细胞增殖实验、软琼脂成瘤实验、细胞划痕实验、Transwell细胞侵袭实验分别检测肿瘤细胞的增殖、体外成瘤、迁移和侵袭能力。结果 E2组与Mock组MCF-7细胞24、48、72和96 h时吸光度值比较,经重复测量设计的方差分析,结果:(1)不同时间点吸光度值比较,差异有统计学意义(P <0.05);(2)两组吸光度值比较,差异有统计学意义(P <0.05),与Mock组比较,E2组72和96 h时细胞增殖能力较Mock组提高(P <0.05);(3)两组吸光度值变化趋势比较,差异有统计学意义(P <0.05)。与Mock组相比,E2组MALAT-1相对表达量升高(P <0.05),miR-26a、miR-26b mRNA相对表达量下降(P <0.05)。高表达miR-26b的乳腺癌患者的生存情况优于低表达miR-26b组,死亡风险更低(P <0.05),低表达miR-26a组患者的生存情况优于高表达miR-26a组(P <0.05),用Cox比例风险回归模型,将miR-26a作为一个独立的预后因素来比较,两组患者的死亡风险比较无差异(P>0.05)。与LV-miR-26b-ctrl组比较,LV-miR-26b-ctrl/E2组乳腺癌细胞的MALAT-1相对表达量升高(P <0.05),与LV-miR-26b-ctrl/E2组比较,LV-miR-26b/E2组乳腺癌细胞的MALAT-1相对表达量降低(P <0.05)。LV-miR-26b-ctrl组、LV-miR-26b-ctrl/E2组、LV-miR-26b/E2组细胞在24、48、72和96 h时吸光度值比较,经重复测量设计的方差分析,结果:(1)不同时间点吸光度值比较,差异有统计学意义(P <0.05);(2)各组吸光度值比较,差异有统计学意义(P <0.05),LV-miR-26b-ctrl/E2组72和96 h时细胞增殖能力明显较LV-miR-26b-ctrl组增强(P <0.05),LV-miR-26b/E2组72和96 h时细胞增殖能力较LV-miR-26b-ctrl/E2组降低(P <0.05);(3)各组吸光度值变化趋势比较,差异有统计学意义(P <0.05)。E2处理后的LV-miR-26b-ctrl肿瘤细胞增殖和体外成瘤能力增强。与LV-miR-26bctrl/E2组比较,LV-miR-26b/E2组肿瘤细胞的增殖和体外成瘤能力降低。在24 h时,LV-miR-26b-ctrl/E2组细胞划痕间隙较LV-miR-26b-ctrl组变窄,LV-miR-26b/E2组24 h时细胞的划痕间隙较LV-miR-26bctrl/E2组明显增宽。LV-miR-26b-ctrl/E2组Transwell小室下方的乳腺癌细胞数量较LV-miR-26b-ctrl组增多,LV-miR-26b/E2组的肿瘤细胞数量较LV-miR-26b-ctrl/E2组减少。结论 下调MALAT-1可能是miR-26b抑制乳腺癌恶性生物学行为的分子机制之一,miR-26b有望成为乳腺癌治疗的调控靶点。 展开更多
关键词 乳腺癌 microRNA-26b MALAT-1 雌二醇 lncRNA 浸润 转移
下载PDF
PD-1/PD-L1抑制剂联合贝伐珠单抗在晚期三阴性乳腺癌中的应用价值
13
作者 闫晓倩 柯洋 +2 位作者 冯沛贝 彭湃 易善永 《罕少疾病杂志》 2024年第1期73-74,共2页
目的探究程序性死亡受体1(PD-1)/程序性死亡受体-配体1(PD-L1)抑制剂联合贝伐珠单抗在晚期三阴性乳腺癌(TNBC)中的应用效果。方法选择本院2020年1月~2021年12月诊治的102例晚期TNBC患者,按治疗方式不同将其设为47例对照组(PD-1/PD-L1抑... 目的探究程序性死亡受体1(PD-1)/程序性死亡受体-配体1(PD-L1)抑制剂联合贝伐珠单抗在晚期三阴性乳腺癌(TNBC)中的应用效果。方法选择本院2020年1月~2021年12月诊治的102例晚期TNBC患者,按治疗方式不同将其设为47例对照组(PD-1/PD-L1抑制剂治疗)与55例研究组(PD-1/PD-L1抑制剂联合贝伐珠单抗治疗)。比较两组疗效、不良反应及预后情况。结果研究组总体客观缓解率36.36%,比对照组17.02%高(P<0.05)。两组不良反应总发生率对比无差异(P>0.05)。研究组无进展生存期比对照组高(P<0.05);两组复发率对比无差异(P>0.05)。结论PD-1/PD-L1抑制剂联合贝伐珠单抗在晚期三阴性乳腺癌中的疗效确切,可改善患者短期预后,且安全性可控,临床应用价值较高。 展开更多
关键词 三阴性乳腺癌 PD-1/PD-L1抑制剂 贝伐珠单抗 预后
下载PDF
Effect of Trastuzumab on Notch-1 Signaling Pathway in Breast Cancer SK-BR3 Cells 被引量:3
14
作者 Ming Han Hua-yu Deng Rong Jiang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2012年第3期213-219,共7页
Objective: To investigate the effects and mechanisms of trastuzumab on Notch-1 pathway in breast cancer cells, recognizing the significance of Notch-1 signaling pathway in trastuzumab resistance. Methods: Immunocyto... Objective: To investigate the effects and mechanisms of trastuzumab on Notch-1 pathway in breast cancer cells, recognizing the significance of Notch-1 signaling pathway in trastuzumab resistance. Methods: Immunocytochemistry staining and Western blotting were employed to justify the expression of Notch-1 protein in HER2-overexpressing SK-BR3 cells and HER2-non-overexpressing breast cancer MDA-MB-231 cells. Western blotting and reverse transcription PCR (RT-PCR) were used to detect the activated Notch-1 and Notch-1 target gene HES-1 mRNA expression after SK-BR3 cells were treated with trastuzumab. Double immunofluorescence staining and co-immunoprecipitation were used to analyze the relationship of Notch-1 and HER2 proteins. Results: The level of Notch-1 nuclear localization and activated Notch-1 proteins in HER2-overexpressing cells were significantly lower than in HER2-non-overexpressing cells (P0.01), and the expressions of activated Notch-1 and HES-1 mRNA were obviously increased after trastuzumab treatment (P0.05), but HER2 expression did not change significantly for trastuzumab treating (P0.05). Moreover, Notch-1 was discovered to co-localize and interact with HER2 in SK-BR3 cells. Conclusion: Overexpression of HER2 decreased Notch-1 activity by the formation of a HER2-Notch1 complex, and trastuzumab can restore the activity of Notch-1 signaling pathway, which could be associated with cell resistance to trastuzumab. 展开更多
关键词 NOTCH-1 HER2 TRASTUZUMAB breast cancer
下载PDF
槐耳颗粒通过抑制Bmi-1与CD133表达减少三阴性乳腺癌全身转移的研究 被引量:1
15
作者 李竞岳 姜大庆 《实用中医内科杂志》 2024年第3期96-99,共4页
目的研究在不同给药方式下槐耳颗粒对三阴性乳腺癌细胞的作用效果,及槐耳颗粒是否可以影响Bmi-1进而调节肿瘤细胞CD133表达以发挥抑制肿瘤细胞转移的作用。方法选择40只3~4周龄雌性裸鼠随机分成四组,预防组、预防及治疗组、治疗组分别... 目的研究在不同给药方式下槐耳颗粒对三阴性乳腺癌细胞的作用效果,及槐耳颗粒是否可以影响Bmi-1进而调节肿瘤细胞CD133表达以发挥抑制肿瘤细胞转移的作用。方法选择40只3~4周龄雌性裸鼠随机分成四组,预防组、预防及治疗组、治疗组分别于建模前3周、建模前及建模后3周、建模后3周口服给予槐耳清膏溶液,对照组不给予药物治疗;建模方式采用左心室注射的方法建立三阴性乳腺癌全身转移模型,建模后六周观察期后统一处死裸鼠并取标本;通过Kaplan-Meier法分析裸鼠生存时间,免疫组化法检测裸鼠转移灶内CD133及Bmi-1的表达,组间比较采用方差分析。结果预防及治疗组裸鼠的生存时间最长(MST=42d),其次为治疗组(MST=39d),再次为预防组(MST=38 d),对照组裸鼠的生存时间最短(MST=32d);预防及治疗组的Bmi-1平均表达最低,对照组的Bmi-1平均表达最高,不同给药方式与Bmi-1的表达之间存在显著性差异(P<0.05);预防及治疗组的CD133平均表达最低,对照组的CD133平均表达最高,不同给药方式与CD133的表达之间存在显著性差异(P<0.05)。结论槐耳颗粒对三阴性乳腺癌全身转移具有预防及治疗作用;槐耳颗粒可能通过激活Bmi-1凋亡基因从而减少了三阴性乳腺癌干细胞CD133的比例,进而发挥了预防及治疗三阴性乳腺癌全身转移的作用。 展开更多
关键词 三阴性乳腺癌 槐耳颗粒 CD133 BMI-1 乳腺癌全身转移
下载PDF
剪接因子3B亚单位1在乳腺癌组织中的表达及与患者临床病理特征关系
16
作者 陈丽丽 施民新 薛丽娟 《陕西医学杂志》 CAS 2024年第2期262-265,共4页
目的:探讨剪接因子3B亚单位1(SF3B1)在乳腺癌组织中的表达及与患者临床病理特征的关系。方法:分析88例乳腺癌患者乳腺癌组织和癌旁组织SF3B1的表达水平,评估SF3B1对乳腺癌的诊断价值,比较SF3B1高表达组与低表达组临床病理特征差异。结果... 目的:探讨剪接因子3B亚单位1(SF3B1)在乳腺癌组织中的表达及与患者临床病理特征的关系。方法:分析88例乳腺癌患者乳腺癌组织和癌旁组织SF3B1的表达水平,评估SF3B1对乳腺癌的诊断价值,比较SF3B1高表达组与低表达组临床病理特征差异。结果:乳腺癌组织SF3B1表达明显高于癌旁组织(P<0.05);SF3B1诊断乳腺癌的AUC为0.713;SF3B1诊断乳腺癌的最佳截断值为110.72。高表达组年龄明显高于低表达组,淋巴结转移为N 0的比例明显低于低表达组,两组病理学分级比较差异有统计学意义(P<0.05)。结论:SF3B1在乳腺癌组织中的表达明显上调,在诊断乳腺癌方面效能较好,与临床病理参数有关,可能参与了乳腺癌的发生、侵袭和转移过程的调控。 展开更多
关键词 乳腺癌 剪接因子3B亚单位1 诊断 临床病理 淋巴结转移 受试者工作特征曲线
下载PDF
Expression of Gli1 in the hedgehog signaling pathway and breast cancer recurrence 被引量:6
17
作者 Naoko Takebe Sally Hunsberger Sherry X.Yang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2012年第4期257-258,共2页
The hedgehog (Hh) signaling pathway plays an essential role in the embryonic development and homeostasis of diverse adult tissues, and its deregulation has been implicated in the tumorigenesis and metastasis of vari... The hedgehog (Hh) signaling pathway plays an essential role in the embryonic development and homeostasis of diverse adult tissues, and its deregulation has been implicated in the tumorigenesis and metastasis of various malignancies including breast cancer. Aberrant activation of the Hh pathway includes the following mechanisms: (I) Hh ligand-independent mechanism - Loss of function mutations in the Hh receptor Patched 1 (PTCH1) or gain of function mutations in the Smoothened (SMO) lead to constitutive activation of this pathway; (II) Autocrine signaling- Ith ligand produced by tumor cells stimulates the Hh signaling in tumor cells; (III) Paracrine signaling - tumor cell produced-Hh ligand activates stromal and endothelial cells that produce growth factors in microenvironment for supporting tumor growth and survival; and (IV) Reverse paracrine signaling - Hh ligand produced by stromal cells support tumor growth and survival. Upon the pathway activation, the Gli transcription factors, effectors of the Hh signaling, activate or inhibit transcription by binding to their responsive genes and interacting with the transcriptional complex. The Gli transcription factor family includes Glil, Gli2, and Gli3 (1). Glil is a transcriptional activator whose expression has been recognized as an activation state of the Hh signaling pathway, Gli2 is either an activator or repressor, and Gli3 is a strong repressor of transcriptional activities. To date, a ligand-dependent autocrine model of activating the Hh signaling has been described in breast cancer, and both an autocrine and paracrine mechanisms in colorectal cancer, pancreatic cancer and prostate cancer (2,3). Notably, a ligand-independent mechanism (mutationsin PTCHI and SMO) of the signaling has been well demonstrated in basal cell carcinoma and medulloblastoma (4,5). 展开更多
关键词 CELL Expression of Gli1 in the hedgehog signaling pathway and breast cancer recurrence
下载PDF
MAT1 correlates with molecular subtypes and predicts poor survival in breast cancer 被引量:2
18
作者 Hanxiao Xu Xianguang Bai +3 位作者 Shengnan Yu Qian Liu Richard G Pestell Kongming Wu 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2018年第3期351-363,共13页
Objective:Menage a trois 1(MAT1)is a targeting subunit of cyclin-dependent kinase-activating kinase and general transcription factor IIH kinase,which modulates cell cycle,transcription and DNA repair.Its dysregulat... Objective:Menage a trois 1(MAT1)is a targeting subunit of cyclin-dependent kinase-activating kinase and general transcription factor IIH kinase,which modulates cell cycle,transcription and DNA repair.Its dysregulation is responsible for diseases including cancers.To further explore the role of MAT1 in breast cancer,we investigated the pathways in which MAT1 might be involved,the association between MAT1 and molecular subtypes,and the role of MAT1 in clinical outcomes of breast cancer patients.Methods:We conducted immunohistochemistry staining on tissue microarray and immunofluorescence staining on sections of MAT1 stable breast cancer cells.Also,we performed Kyoto Encyclopedia of Genes and Genomes pathway analysis,correlation analysis and prognosis analysis on public databases.Results:MAT1 was involved in multiple pathways including normal physiology signaling and disease-related signaling.Furthermore,MAT1 positively correlated with the protein status of estrogen receptor and progesterone receptor,and was enriched in luminal-type and human epidermal growth factor receptor 2-enriched breast cancer in comparison with basal-like subtype at both m RNA and protein levels.Correlation analysis revealed significant association between MAT1 m RNA amount and epithelial markers,mesenchymal markers,cancer stem cell markers,apoptosis markers,transcription markers and oncogenes.Consistently,the results of immunofluorescence stain indicated that MAT1 overexpression enhanced the protein abundance of epidermal growth factor receptor,vimentin,sex determining region Y-box 2 and sine oculis homeobox homolog 1.Importantly,Kaplan-Meier Plotter analysis reflected that MAT1 could serve as a prognostic biomarker predicting worse relapse-free survival and metastasis-free survival.Conclusions:MAT1 is correlated with molecular subtypes and is associated with unfavorable prognosis for breast cancer patients. 展开更多
关键词 Menage a trois 1(MAT1) breast cancer molecular subtypes PROGNOSIS PROLIFERATION
下载PDF
Transfer of p14ARF gene in drug-resistant human breast cancer MCF-7/Adr cells inhibits proliferation and reduces doxorubicin resistance 被引量:3
19
作者 范国昌 吴祖泽 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2000年第3期19-25,共7页
Objective: To elucidate the effect of p14ARF gene on multidrug-resistant tumor cells. Methods: We transferred a p14ARF cDNA into p53-mutated MCF-7/Adr human breast cancer cells. Results: In this report we demonstrate... Objective: To elucidate the effect of p14ARF gene on multidrug-resistant tumor cells. Methods: We transferred a p14ARF cDNA into p53-mutated MCF-7/Adr human breast cancer cells. Results: In this report we demonstrated for the first time that p14ARF expression was able to greatly inhibit the MCF-7/Adr cell proliferation. Furthermore, p14ARF expression resulted in decreases in MDR1 mRNA and P-glycoprotein production, which linked with the reducing resistance of MCF-7/Adr cells to doxorubicin. Conclusion: These results imply that drug resistance might be effectively reversed with the wild-type p14ARF expression in human breast cancer cells. 展开更多
关键词 P14ARF MDR-1 P-GLYCOPROTEIN DOXORUBICIN breast cancer tumor suppression
下载PDF
PD-1抑制剂联合抗血管生成治疗晚期三阴性乳腺癌患者临床疗效及预后分析
20
作者 殷雨来 张银旭 +4 位作者 任悦 张辉 白杰 王遵义 张晓宇 《中国肿瘤外科杂志》 CAS 2024年第1期76-81,共6页
目的探究PD-1抑制剂卡瑞丽珠单抗联合VEGFR2抑制剂阿帕替尼治疗晚期三阴性乳腺癌(TNBC)患者的临床疗效和预后分析。方法纳入2019年12月至2021年12月期间沧州市中心医院收治的82例晚期三阴性乳腺癌患者,按照治疗方法分为观察组(n=41)和... 目的探究PD-1抑制剂卡瑞丽珠单抗联合VEGFR2抑制剂阿帕替尼治疗晚期三阴性乳腺癌(TNBC)患者的临床疗效和预后分析。方法纳入2019年12月至2021年12月期间沧州市中心医院收治的82例晚期三阴性乳腺癌患者,按照治疗方法分为观察组(n=41)和对照组(n=41)。在白蛋白紫杉醇常规治疗260 mg/m 2,d1,21 d为1个治疗周期,连续使用4个周期的基础上,对照组加卡瑞丽珠单抗治疗200 mg/次,21 d为一个周期,连续使用4个周期;观察组采用卡瑞丽珠单抗200 mg/次,21 d为一个周期,连续使用4个周期,联合阿帕替尼治疗250 mg/次进行口服,1日/次,28 d为1个治疗周期,持续使用3个周期。并从接受治疗开始对两组患者进行为期1年的随访。观察两组的客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)和总生存期(OS),并比较治疗前后两组的肿瘤标志物水平(CEA、CA153、CA125)、免疫相关指标(T细胞绝对值计数)、预后指标(TK1、VEGF、MUC1、CD44v6)以及不良反应的发生情况。其中主要结局指标为ORR及OS,其余为次要结局指标。结果对两组临床疗效进行评估显示,观察组患者的ORR(48.8%)和DCR(73.2%)均优于对照组(分别为24.4%和46.3%),差异具有统计学意义(P<0.05);观察组和对照组的中位PFS分别为6.80个月(95%CI:6.17~7.43)和4.70个月(95%CI:3.32~6.08),观察组相对于对照组进展的风险比HR为0.537(95%CI:0.337~0.857);观察组和对照组的中位OS分别为10.90个月(95%CI:9.39~12.41)和7.60个月(95%CI:6.97~8.23),观察组相对于对照组死亡的风险比HR为0.406(95%CI:0.241~0.684);观察组的PFS和OS均长于对照组(P<0.05);观察组肿瘤标志物CEA、CA153水平均低于对照组(P<0.001);两组CA125水平及TK1水平差异无统计学意义(P>0.05);观察组VEGF、MUC1、CD44v6水平比对照组低(P<0.001);观察组T细胞绝对值计数高于对照组(P<0.05)。结论PD-1抑制剂卡瑞丽珠单抗联合VEGFR2抑制剂阿帕替尼治疗晚期TNBC患者,临床疗效较为可观,使患者的预后和免疫功能得到了改善,并且安全性相对可控。 展开更多
关键词 三阴性乳腺癌 晚期乳腺癌 PD-1抑制剂 抗血管治疗 卡瑞丽珠单抗 阿帕替尼 白蛋白紫杉醇
下载PDF
上一页 1 2 67 下一页 到第
使用帮助 返回顶部